Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05086081 · ClinicalTrials.gov registry record
Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 28,389
- Enrollment target
NCT05086081: Completed study, sponsored by Brigham and Women's Hospital.
NCT05086081 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 28,389 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05086081 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 28,389 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Claims-based algorithm: Relative hazard of composite of death, myocardial infarction, or stroke at 1 year after randomization
Interventions
- DRUG Ticagrelor 90mg
- DRUG Prasugrel 10mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28,389 participants |
| Start Date | 2020-10-10 |
| Est. Completion | 2021-09-10 |
What the finished NCT05086081 record still lists
NCT05086081 is an observational study that tracks outcomes without assigning an intervention. Its 28,389 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Ticagrelor 90mg is the first listed.
NCT05086081 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05086081 about?
NCT05086081 is a clinical study titled "Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT05086081?
This trial is currently completed. The enrollment target is 28,389 participants. The study started on 2020-10-10. Estimated completion is 2021-09-10.
What interventions are being tested in trial NCT05086081?
The interventions under investigation include: Ticagrelor 90mg (DRUG), Prasugrel 10mg (DRUG).
Who is sponsoring clinical trial NCT05086081?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04494945 · 27,500 participants · NA
Identifying and Caring for Individuals With Inherited Cancer Syndrome
- NCT04678193 · 27,000 participants
COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
- NCT03053193 · 30,000 participants
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI